LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice
暂无分享,去创建一个
Li Zhao | Xiaomin Ren | Zuoying Hu | Qing Ge | Chen Liu | Yihui Yu | C. Pan
[1] Hiroshi Ito,et al. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats , 2019, Cardiology journal.
[2] Zuo-ying Hu,et al. Feature article: LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis , 2019, Experimental biology and medicine.
[3] Yaeni Kim,et al. Inhibition of lymphatic proliferation by the selective VEGFR-3 inhibitor SAR131675 ameliorates diabetic nephropathy in db/db mice , 2019, Cell Death & Disease.
[4] H. Moradi,et al. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease. , 2018, Journal of cardiac failure.
[5] Ming-Hai Wang,et al. The optimum marker for the detection of lymphatic vessels , 2017, Molecular and clinical oncology.
[6] J. Ge,et al. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. , 2017, Journal of molecular and cellular cardiology.
[7] P. Valet,et al. Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarction. , 2017, JCI insight.
[8] P. Mulder,et al. Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction , 2016, Circulation.
[9] K. Alitalo,et al. Ischemia–Reperfusion Injury Enhances Lymphatic Endothelial VEGFR3 and Rejection in Cardiac Allografts , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] S. Miura,et al. LCZ696, an angiotensin receptor–neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin‐induced diabetic mice , 2016, European journal of heart failure.
[11] Yu Hasegawa,et al. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone. , 2015, American journal of hypertension.
[12] C. Carr,et al. Cardiac lymphatics are heterogeneous in origin and respond to injury , 2015, Nature.
[13] D. Atar,et al. Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy , 2015, Circulation. Heart failure.
[14] E. Sevick-Muraca,et al. Cytokines are systemic effectors of lymphatic function in acute inflammation. , 2013, Cytokine.
[15] A. Voors,et al. The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure , 2013, Expert opinion on investigational drugs.
[16] S. Solomon,et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.
[17] G. Koh,et al. Regulation and implications of inflammatory lymphangiogenesis. , 2012, Trends in immunology.
[18] M. May,et al. LYVE-1 upregulation and lymphatic invasion correlate with adverse prognostic factors and lymph node metastasis in neuroblastoma , 2012, Virchows Archiv.
[19] R. Sarangapani,et al. Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi) , 2010, Journal of clinical pharmacology.
[20] N. Frangogiannis,et al. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload , 2009, Histochemistry and Cell Biology.
[21] G. Watkins,et al. Lymphangiogenesis and lymph node metastasis in breast cancer , 2008, Molecular Cancer.
[22] M. Hori,et al. Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice. , 2005, Cardiovascular research.
[23] M. Hori,et al. Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. , 2002, American journal of physiology. Heart and circulatory physiology.
[24] H. Granger,et al. Reactive oxygen metabolites inhibit spontaneous lymphatic contractions. , 1991, The American journal of physiology.